

COBALT, ANTIMONY COMPOUNDS, AND WEAPONS-GRADE TUNGSTEN ALLOY

VOLUME 131

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 2–18 March 2022

LYON, FRANCE - 2023

IARC MONOGRAPHS
ON THE IDENTIFICATION
OF CARCINOGENIC HAZARDS
TO HUMANS

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review	11
4. The Working Group and other meeting participants.....	11
5. Working procedures.....	13
6. Overview of the scientific review and evaluation process	14
7. Responsibilities of the Working Group.....	16
B. SCIENTIFIC REVIEW AND EVALUATION	17
1. Exposure characterization	17
2. Studies of cancer in humans.....	20
3. Studies of cancer in experimental animals.....	25
4. Mechanistic evidence	28
5. Summary of data reported.....	31
6. Evaluation and rationale.....	32
References.....	37
GENERAL REMARKS	41
COBALT METAL (WITHOUT TUNGSTEN CARBIDE) AND SOME COBALT COMPOUNDS ...	49
1. Exposure Characterization	49
1.1 Identification of the agent	49
1.2 Production and use.....	55
1.3 Detection and quantification.....	59
1.4 Occurrence and exposure.....	63
1.5 Regulations and guidelines	93
1.6 Quality of exposure assessment in key epidemiological studies of cancer and mechanistic studies in humans	95

2. Cancer in Humans	108
2.1 Lung cancer	114
2.2 Breast cancer	125
2.3 Cancer of the oral cavity, pharynx, larynx, and oesophagus	137
2.4 Other cancers and all cancers combined	146
2.5 Evidence synthesis for cancer in humans	148
3. Cancer in Experimental Animals	151
3.1 Cobalt metal	151
3.2 Soluble cobalt(II) salts	183
3.3 Insoluble cobalt(II) oxide, cobalt(II,III) oxide, and cobalt(II) sulfide	189
3.4 Other cobalt(II) compounds	194
3.5 Evidence synthesis for cancer in experimental animals	194
4. Mechanistic Evidence	196
4.1 Absorption, distribution, metabolism, and excretion	196
4.2 Evidence relevant to key characteristics of carcinogens	204
5. Summary of Data Reported	308
5.1 Exposure characterization	308
5.2 Cancer in humans	308
5.3 Cancer in experimental animals	309
5.4 Mechanistic evidence	310
6. Evaluation and Rationale	314
6.1 Cancer in humans	314
6.2 Cancer in experimental animals	314
6.3 Mechanistic evidence	315
6.4 Overall evaluation	315
6.5 Rationale	315
References	316
TRIVALENT AND PENTAVALENT ANTIMONY	357
1. Exposure Characterization	357
1.1 Identification of the agent	357
1.2 Production and use	360
1.3 Detection and quantification	363
1.4 Occurrence and exposure	368
1.5 Regulations and guidelines	397
1.6 Quality of exposure assessment in key epidemiological studies of cancer and mechanistic studies in humans	401
2. Cancer in Humans	411
2.1 Cancer of the lung and other parts of the respiratory tract	412
2.2 Cancer of the stomach, colon, rectum, and other digestive organs	418
2.3 Cancer of the breast	428
2.4 Cancer of the thyroid and other sites, including all cancers combined	437
2.5 Evidence synthesis for cancer in humans	443

3. Cancer in Experimental Animals	446
3.1 Mouse	446
3.2 Rat	455
3.3 Evidence synthesis for cancer in experimental animals	459
4. Mechanistic Evidence	460
4.1 Absorption, distribution, metabolism, and excretion	460
4.2 Evidence relevant to key characteristics of carcinogens	467
5. Summary of Data Reported	511
5.1 Exposure characterization	511
5.2 Cancer in humans	512
5.3 Cancer in experimental animals	512
5.4 Mechanistic evidence	513
6. Evaluation and Rationale	515
6.1 Cancer in humans	515
6.2 Cancer in experimental animals	515
6.3 Mechanistic evidence	515
6.4 Overall evaluation	515
6.5 Rationale	515
References	516
WEAPONS-GRADE TUNGSTEN (WITH NICKEL AND COBALT) ALLOY.....	539
1. Exposure Characterization	539
1.1 Identification of the agent	539
1.2 Production and use	540
1.3 Detection and quantification	541
1.4 Occurrence and exposure	544
1.5 Regulations and guidelines	548
1.6 Quality of exposure assessment in key epidemiological studies of cancer and mechanistic studies in humans	548
2. Cancer in Humans	551
3. Cancer in Experimental Animals	551
3.1 Mouse	551
3.2 Rat	551
3.3 Evidence synthesis for cancer in experimental animals	556
4. Mechanistic Evidence	557
4.1 Absorption, distribution, metabolism, and excretion	557
4.2 Evidence relevant to key characteristics of carcinogens	559
5. Summary of Data Reported	574
5.1 Exposure characterization	574
5.2 Cancer in humans	574
5.3 Cancer in experimental animals	574
5.4 Mechanistic evidence	574

6. Evaluation and Rationale.....	576
6.1 Cancer in humans.....	576
6.2 Cancer in experimental animals.....	576
6.3 Mechanistic evidence.....	576
6.4 Overall evaluation.....	576
6.5 Rationale.....	576
References.....	576
LIST OF ABBREVIATIONS.....	581
ANNEX 1. Supplementary material for Section 1, Exposure Characterization.....	585
ANNEX 2. Supplementary material for Section 2, Cancer in Humans.....	587
ANNEX 3. Supplementary material for Section 4, Mechanistic Evidence.....	589
ANNEX 4. Supplementary material for Section 4, Evaluation of high-throughput in vitro toxicity screening data.....	591
SUMMARY OF FINAL EVALUATIONS.....	593